Re-operative neck surgery for well-differentiated thyroid cancer of follicular origin

Journal of Surgical Oncology

Volumn 94, Issue 8, 2006, Pages 714-718

  Monchik, Jack M ^a,b   Delellis, Ronald A ^a  

^a RHODE ISLAND HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

Follicular carcinoma; Papillary carcinoma; Surgery; Thyroid cancer

Indexed keywords

CANCER RECURRENCE; DIAGNOSTIC VALUE; ECHOGRAPHY; HEAD AND NECK SURGERY; HISTOPATHOLOGY; HUMAN; INTRAOPERATIVE PERIOD; LYMPH NODE DISSECTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REOPERATION; REVIEW; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TISSUE DIFFERENTIATION;

EID: 33845427574     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20693     Document Type: Review

References (37)

1. Singer PA, Cooper DS, Daniels GH, et al.: Treatment guidelines for patients with thyroid nodules and well-differentiated cancer. Arch intern Med 1996;156:2165-2172.
2. Cady B: Our AMES is true; how an old concept still hits the mark - or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg 1997;174:461-468.
3. Cady B: Staging in thyroid carcinoma cancer 1998;83:844-847.
4. Shaha AR, Shah JP, Loree TR: Low-risk differentiated thyroid cancer: The need for selective treatment. Ann Surg Oncol 1997;4:328-333.
5. Cady B, Rossi R: An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988;104:947-953.
6. Hay ID, Grant CS, Taylor WF, et al.: Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: A retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987;102:1088-1095.
7. Hay ID, Thompson GB, Grant CS, et al.: Papillary thyroid carcinoma managed at the Mayo Clinic during 6 decades (1940-1999): Temporal trends in initial therapy and long term outcome in 2444 consecutively treated patients. World J Surgery 2002;26:879-885.
8. Sherman SI, Brierley JD, Sperling M, et al.: Prospective multicenter study of thyroid carcinoma treatment: Initial analysis of staging and outcome. National Cancer Treatment Cooperative Study Registry Group. Cancer 1998;83:1012-1021.
9. Siperstein AE, Zeng ZH, Gum ET, et al.: Adenylate cyclase activity as a predictor of thyroid tumor aggressiveness. World J Surg 1988;12:528-532.
10. Duh Qy, Siperstein AE, Miller RA, et al.: Epidermal growth factor receptors and adenylate cyclase activity in human thyroid tissues. World J Surg 410-417.
11. Hay ID: Papillary thyroid carcinoma. Endocrinol Metab Clin North Am 1990;19:545-576.
12. Backdahl M, Carstensen J, Aver G, et al.: Statistical evaluation of the diagnostic valve of nuclear DNA content in papillary, follicular, and medullary thyroid tumors. World J Surg 1986;10:974-979.
13. Goretszki PE, Lyons J, Stacy-Phipps SS, et al.: Mutational activation of RAS and GSP oncogenes in differentiated thyroid cancer and their biological implications. World J Surg 1992;16:576-581.
14. Lemoine NR, Mayall ES, Wyllie FS, et al.: Activated ras oncogenes in human thyroid cancers. Cancer Res 1998;48:4459-4463.
15. Santoro M, Nathan Berlingieri Mt, et al.: Molecular characterization of RET/PTC3 a novel rearranged version of the RET protooncogene in a human papillary carcinoma. Oncogene 1994;9:509-516.
16. Hay ID, Grant CS, Van Heerden JA: Papillary thyroid microcarcinoma: A Study of 535 cases observed in a 50-year period. Surgery 1992;112:1139-1147.
17. Cady B, Sedgwick CE, Meissner WA, et al.: Risk factor analysis in differentiated thyroid cancer. Cancer 1979;43:810-820.
18. Hay ID, Grant CS, Bergstrah MS, et al.: Unilateral total lobectomy: Is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma. Surgery 1998;125:958-996.
19. DeGroot LJ, Kaplan EL, McCormick M, et al.: Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990;71:414-424.
20. Rosai J, Carcangiu ML, DeLellis RA: Tumors of the thyroid gland. Third Series, Fascicle 5. Armed Forces Institute of Pathology 1992; 49-53.
21. Sobrinho-Simoes M, Asa SL, Kroll TG, et al.: Follicular carcinoma. In De Lellis RA, Loyd RV, Hertz PU, Eng C (eds): Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press, 2004:67-72.
22. Lang W, Choritz H, Hundeshagen H: Risk factors in follicular thyroid carcinoma. A retrospective follow-up covering a 14 year period with emphasis on morphological findings. Am J Surg Pathol 1986;10:246-255.
23. Rosai J: Rosai and Ackerman's Surgical Pathology, 9th edition. Volume 1. Edinburg: Mosby Publishing, 2004.
24. LiVolsi VA, Baloch Z: Follicular neoplasmsof the thyroid. Views, biases and experiences. Adv Anat Pathol 2004; 11279-11287.
25. Thompson LD, Wienke JA, Paal E, et al.: A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature. Cancer 2001;91:505-524.
26. Van Heerden JA, Hay ID, Goellner R, et al.: Follicular thyroid carcinoma with capsular invasion only: A non-threatening malignancy. Surgery 1992;112:1130-1136.
27. Hoos A, Stojadinovic A, Singh B, et al.: Clinical significance of molecular expression profiles of Hurthle cell tumors of the thyroid gland analyzed via issue microassays. Am J Pathol 2002;160:175-183.
28. Herrera MF, Hay ID, WU PS, et al.: Hurthle cell (oxyphilic) papillary thyroid carcinoma: A variant with more aggressive biologic behavior. World J Surg 1992;16:669-775.
29. Chen H, Nicol TL, Udelsman R: Follicular lesion of the thyroid: Does frozen section evaluation alter operative management? Ann Surg 1995;222:101-106.
30. Chen H, Nicol TL, Zeiger MA, et al.: Hurthle cell neoplasms of the thyroid are there factors predictive of a malignancy? Ann Surg 1998;222:542-546.
31. Kouvaraki MA, Shapiro SE, Fornage BD, et al.: Role of preoperative ultrasonography in the surgical management of patient with thyroid cancer. Surgery 2003;134:946-954.
32. Schlumberger M, Berg G, Cohen O, et al.: Follow-up of low-risk patients with differentiated thyroid carcinoma: A European perspective. Eur J Endocrinol 2004;105:105-112.
33. Cooper DS, Doherty GM, Bryan R, et al.: Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:1-29.
34. Frasoldati A, Pesenti M, Gallo M, et al.: Diagnosis of neck recurrences in patients with differentiated thyroid cancer. Cancer 2003;97:90-96.
35. Dupuy DE, Monchik JM, Decrea C, et al.: Radiofrequency ablation of regional recurrence from well differentiated thyroid malignancy. Surgery 2001;130:971-977.
36. Lewis BD, Hay ID, Charboneau JW, et al.: Ethanol ablation of regional recurrence from well differentiated thyroid malignancy. Surgery 2001;130:971-977.
37. Monchik JM, Donatini G, Iannuccilli J, Dupuy D: Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well differentiated thyroid cancer. Ann Surg 2006;244:296-304.